55 related articles for article (PubMed ID: 27691399)
21. Systematic Activity Maturation of a Single-Domain Antibody with Non-canonical Amino Acids through Chemical Mutagenesis.
Lindstedt PR; Aprile FA; Sormanni P; Rakoto R; Dobson CM; Bernardes GJL; Vendruscolo M
Cell Chem Biol; 2021 Jan; 28(1):70-77.e5. PubMed ID: 33217338
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of the type III interferon complex and its applications in protein engineering.
Grubbe WS; Byléhn F; Alvarado W; de Pablo JJ; Mendoza JL
Biophys J; 2023 Nov; 122(21):4254-4263. PubMed ID: 37794680
[TBL] [Abstract][Full Text] [Related]
23. Low-Barrier Hydrogen Bond Determines Target-Binding Affinity and Specificity of the Antitubercular Drug Bedaquiline.
Słabońska J; Sappati S; Marciniak A; Czub J
ACS Med Chem Lett; 2024 Feb; 15(2):265-269. PubMed ID: 38352844
[TBL] [Abstract][Full Text] [Related]
24. Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systems.
Nikkhoi SK; Rahbarizadeh F; Ahmadvand D
Protein Expr Purif; 2017 Jan; 129():115-121. PubMed ID: 27693491
[TBL] [Abstract][Full Text] [Related]
25. Optimization of an anti-HER2 nanobody expression using the Taguchi method.
Farasat A; Rahbarizadeh F; Ahmadvand D; Yazdian F
Prep Biochem Biotechnol; 2017 Sep; 47(8):795-803. PubMed ID: 28636463
[TBL] [Abstract][Full Text] [Related]
26. A Conjugate of an Anti-Epidermal Growth Factor Receptor (EGFR) VHH and a Cell-Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation.
van Lith SAM; van den Brand D; Wallbrecher R; van Duijnhoven SMJ; Brock R; Leenders WPJ
Chembiochem; 2017 Dec; 18(24):2390-2394. PubMed ID: 28994180
[TBL] [Abstract][Full Text] [Related]
27. In silico approach to probe the binding affinity between OMVs harboring the Z
Sepahdar Z; Saghiri R; Miroliaei M; Salimi M
J Mol Model; 2022 Apr; 28(5):113. PubMed ID: 35381900
[TBL] [Abstract][Full Text] [Related]
28. Effects of unsaturated fatty acids (Arachidonic/Oleic Acids) on stability and structural properties of Calprotectin using molecular docking and molecular dynamics simulation approach.
Gheibi N; Ghorbani M; Shariatifar H; Farasat A
PLoS One; 2020; 15(3):e0230780. PubMed ID: 32214349
[TBL] [Abstract][Full Text] [Related]
29. Study of HSA interactions with arachidonic acid using spectroscopic methods revealing molecular dynamics of HSA-AA interactions.
Valojerdi FM; Farasat A; Shariatifar H; Gheibi N
Biomed Rep; 2020 Mar; 12(3):125-133. PubMed ID: 32042421
[TBL] [Abstract][Full Text] [Related]
30. A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8
Tang Z; Mo F; Liu A; Duan S; Yang X; Liang L; Hou X; Yin S; Jiang X; Vasylieva N; Dong J; Barnych B; Hammock BD; Lu X
J Biomed Nanotechnol; 2019 Nov; 15(11):2229-2239. PubMed ID: 31847937
[TBL] [Abstract][Full Text] [Related]
31. In silico assessment of human Calprotectin subunits (S100A8/A9) in presence of sodium and calcium ions using Molecular Dynamics simulation approach.
Gheibi N; Ghorbani M; Shariatifar H; Farasat A
PLoS One; 2019; 14(10):e0224095. PubMed ID: 31622441
[TBL] [Abstract][Full Text] [Related]
32. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.
Arezumand R; Alibakhshi A; Ranjbari J; Ramazani A; Muyldermans S
Front Immunol; 2017; 8():1746. PubMed ID: 29276515
[TBL] [Abstract][Full Text] [Related]
33. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
34. An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes.
Padhi AK; Kumar A; Haruna KI; Sato H; Tamura H; Nagatoishi S; Tsumoto K; Yamaguchi A; Iraha F; Takahashi M; Sakamoto K; Zhang KYJ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34415295
[TBL] [Abstract][Full Text] [Related]
35. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
Verkhivker G
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
[TBL] [Abstract][Full Text] [Related]
36. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
[TBL] [Abstract][Full Text] [Related]
37. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
[TBL] [Abstract][Full Text] [Related]
38. Role of N-glycosylation in EGFR ectodomain ligand binding.
Azimzadeh Irani M; Kannan S; Verma C
Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
